Pulmonary Cell News Volume 11.17 | May 5 2022

    By
    Ishira
    -
    0
    38







    2022-05-05 | PULCN 11.17


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 11.17 – 5 May, 2022
    TOP STORY

    Copy Number Amplification and SP1-Activated lncRNA MELTF-AS1 Regulates Tumorigenesis by Driving Phase Separation of YBX1 to Activate ANXA8 in Non-Small Cell Lung Cancer

    MELTF-AS1 was markedly upregulated in NSCLC. High MELTF-AS1 levels were associated with advanced tumor-node-metastasis stage, high tumor size, and decreased survival time.
    [Oncogene]

    Abstract
    ON1023ORG-Dynamic-Modeling-in-Organoids-728-x-90-b
    PUBLICATIONSRanked by the impact factor of the journal

    KLF4 Regulates TERT Expression in Alveolar Epithelial Cells in Pulmonary Fibrosis

    Scientists delineated the mechanisms by which telomerase reverse transcriptase (TERT) protein expression was regulated in alveolar epithelial cells in pulmonary fibrosis.
    [Cell Death & Disease]

    Full Article

    Airway Epithelial Interferon Response to SARS-CoV-2 Is Inferior to Rhinovirus and Heterologous Rhinovirus Infection Suppresses SARS-CoV-2 Replication

    Bronchial airway epithelial cells from children aged 6–18 years and older adults aged 60–75 years were differentiated ex vivo to generate organotypic cultures.
    [Scientific Reports]

    Full Article

    Liproxstatin-1 Alleviates LPS/IL-13-Induced Bronchial Epithelial Cell Injury and Neutrophilic Asthma in Mice by Inhibiting Ferroptosis

    Bronchial epithelial cells were administered with lipopolysaccharide (LPS) and interleukin-13 (IL-13) to generate a cell injury model that was employed to examine the effect of Liproxstatin-1 on airway epithelial-associated inflammation and ferroptosis.
    [International Immunopharmacology]

    Full Article

    SRY-Related High-Mobility Group Box 9 (SOX9) Alleviates Cigarette Smoke Extract (CSE)-Induced Inflammatory Injury in Human Bronchial Epithelial Cells by Suppressing Stromal Interaction Molecule 1 (STIM1) Expression

    Human bronchial epithelial cells (BEAS-2B) were treated with CSE to construct an in vitro COPD model. The levels of SOX9 and STIM1 in CSE-treated BEAS-2B cells were detected by western blot and RT-qPCR assay.
    [Inflammation Research]

    Abstract

    miRNA-34c-5p Targets Fra-1 to Inhibit Pulmonary Fibrosis Induced by Silica through p53 and PTEN/PI3K/Akt Signaling Pathway

    Through interaction with PTEN/p53, the miRNA-34c-5p/Fra-1 axis inhibited the proliferation and migration of human bronchial epithelial cells stimulated by silica, and promoted cell apoptosis, thereby preventing epithelial-mesenchymal transformation.
    [Environmental Toxicology]

    Abstract

    Human Lung Adenocarcinoma CD47 Is Upregulated by Interferon- and Promotes Tumor Metastasis

    Functionally, interferon-γ (IFNγ)-enhanced CD47 expression facilitated human lung cancer cell invasion both in vitro and in vivo, whereas IFNγ-induced CD47 upregulation and cancer metastasis were blocked by mutating the interferon regulatory factor-1-binding site within CD47 promoter.
    [Molecular Therapy Oncolytics]

    AbstractFull ArticleGraphical Abstract

    POU6F1 Cooperates with RORA to Suppress the Proliferation of Lung Adenocarcinoma by Downregulation HIF1A Signaling Pathway

    In vitro assays, including CCK8, soft agar, transwell, clone formation, wound-healing assay, and nude mouse xenograft models all revealed that POU domain, class 6, transcription factor 1 (POU6F1) inhibited the growth and invasion of lung adenocarcinoma cells.
    [Cell Death & Disease]

    Full Article

    MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer

    Combinatorial treatment of mitochondrial inhibitors with crizotinib revealed inhibitory synergism, suggesting increased reliance on glutamine metabolism and fatty-acid synthesis in chronic ROS1-TKI treated MYC-amplified patient-derived cell line and xenograft cells.
    [Molecular Cancer Research]

    Abstract
    Graphical Abstract

    Mogrol Suppresses Lung Cancer Cell Growth by Activating AMPK-Dependent Autophagic Death and Inducing p53-Dependent Cell Cycle Arrest and Apoptosis

    Mogrol significantly inhibited the proliferation and migration of lung cancer cells, including NSCLC cells, A549, H1299, H1975, and SK-MES-1 cells, with no obvious effect on control human bronchial epithelial cells.
    [Toxicology and Applied Pharmacology]

    AbstractGraphical Abstract

    SNF5 Promotes Cell Proliferation and Immune Evasion in Non-Small Cell Lung Cancer

    Sucrose non-fermenting gene number 5 (SNF5) regulated immune evasion by activating the signal transducer and activator of transcription (STAT3)/ phospho-STAT3 pathway in NSCLC cells.
    [Bioengineered]

    Full ArticleGraphical Abstract
    Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart
    REVIEWS

    Circadian Molecular Clock Disruption in Chronic Pulmonary Diseases

    The authors review circadian clock disruption and discuss candidate clock genes that are altered at the transcriptional or translational level in chronic pulmonary diseases.
    [Trends in Molecular Medicine]

    Abstract

    The Impact of Long-Acting Muscarinic Antagonists on Mucus Hypersecretion and Cough in Chronic Obstructive Pulmonary Disease: A Systematic Review

    Scientists investigate the impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in COPD patients.
    [European Respiratory Review]

    Full Article
    INDUSTRY AND POLICY NEWS

    Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

    Harpoon Therapeutics, Inc. announced that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab for use in the company’s HPN328, a DLL3 targeting TriTAC®, clinical development program.
    [Harpoon Therapeutics, Inc.]

    Press Release

    Algernon Pharmaceuticals Announces Last Patient Treated in Phase II Study of IPF and Chronic Cough

    Algernon Pharmaceuticals Inc. announced that the last patient has completed the treatment period in its Phase II proof of concept study of NP-120 for idiopathic pulmonary fibrosis (IPF) and chronic cough.
    [Algernon Pharmaceuticals, Inc. (GlobeNewswire, Inc.)]

    Press Release

    Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

    Pliant Therapeutics announced that PLN-74809, its oral, dual-selective αvß6/αvß1 integrin inhibitor, has received Fast Track designation from the US FDA for the potential treatment of idiopathic pulmonary fibrosis.
    [Pliant Therapeutics]

    Press Release
    FEATURED EVENT

    Channels in Context: Structure and Function of Ion Channels in Macromolecular Complexes and Native Cells

    September 7 – 11, 2022
    Woods Hole, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Cancer Immunology

    Flanders Institute for Biotechnology – Brussels, Belgium

    Research Fellow – Respiratory Genomics

    Mayo Clinic – Scottsdale, Arizona, United States

    Senior Research Scientist – Pulmonology

    Gilead Sciences, Inc. – Foster City, California, United States

    Research Chair – Lung Regenerative Medicine

    McGill University – Montreal, Quebec, Canada

    Postdoctoral Scholar – Translational Lung Cancer

    The Ohio State University – Columbus, Ohio, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter